Influenza Diagnostics Market Research Report Information By Type of Flu (Type A Flu, Type B Flu, and Type C Flu), By Test Type (Traditional Diagnostic Tests and Molecular Diagnostic Tests), By End User (Hospitals & Clinical Laboratories) - Forecast till 2032

1 Executive Summary

2 Market Introduction

2.1 Definition 18

2.2 Scope Of The Study 18

2.3 Assumptions & Limitations 18

2.3.1 Assumptions 18

2.3.2 Limitations 18

2.4 Market Structure 19

3 Research Methodology

3.1 Research Process 20

3.2 Primary Research 21

3.3 Secondary Research 21

3.4 Market Size Estimation 22

3.5 Forecast Model 23

4 Market Dynamics

4.1 Introduction 24

4.2 Drivers 24

4.2.1 Rising Prevalence Of Influenza 24

4.2.2 Increasing Research Funding For Influenza Diagnosis 25

4.2.3 Increasing Demand For Quick Diagnostic Tests 25

4.3 Restraints 26

4.3.1 Rising Healthcare Cost 26

4.3.2 Inaccuracy In Diagnostic Tests 26

4.4 Opportunities 26

4.4.1 Entering Developing Economies 26

4.5 Market Trends 26

4.5.1 Introduction Of Artificial Intelligence (AI) In Diagnosis Of Influenza 26

4.6 Macroeconomic Indicators 27

5 Market Factor Analysis

5.1 Porter’s Five Forces Analysis 28

5.1.1 Bargaining Power Of Suppliers 28

5.1.2 Bargaining Power Of Buyers 29

5.1.3 Threat Of New Entrants 29

5.1.4 Threat Of Substitutes 29

5.1.5 Intensity Of Rivalry 29

5.2 Value Chain Analysis 29

5.2.1 R&D And Designing 30

5.2.2 Manufacturing 30

5.2.3 Distribution & Sales 30

5.2.4 Post-Sales Services 30

5.3 Pricing Analysis 31

5.4 Investment Opportunities 32

6 Global Influenza Diagnostics Market, By Type Of Flu

6.1 Overview 33

6.2 Type A Flu 34

6.3 Type B Flu 35

6.4 Type C Flu 36

7 Global Influenza Diagnostics Market, By Test Type

7.1 Overview 37

7.2 Traditional Diagnostic Tests 39

7.3 Molecular Diagnostic Tests 40

8 Global Influenza Diagnostics Market, By End User

8.1 Overview 41

8.2 Hospitals & Clinical Laboratories 43

8.3 Point-Of-Care Testing 43

9 Global Influenza Diagnostics Market, By Region

9.1 Overview 44

9.2 Americas 46

9.2.1 North America 50

9.2.1.1 US 53

9.2.1.2 Canada 55

9.2.2 Latin America 58

9.3 Europe 61

9.3.1 Western Europe 64

9.3.1.1 Germany 68

9.3.1.2 France 70

9.3.1.3 UK 73

9.3.1.4 Italy 75

9.3.1.5 Spain 78

9.3.1.6 Rest Of Western Europe 80

9.3.2 Eastern Europe 83

9.4 Asia-Pacific 86

9.4.1 China 90

9.4.2 Japan 92

9.4.3 India 95

9.4.4 Australia 97

9.4.5 South Korea 100

9.4.6 Rest Of Asia-Pacific 102

9.5 Middle East & Africa 105

9.5.1 Saudi Arabia 109

9.5.2 Egypt 111

9.5.3 UAE 114

9.5.4 Rest Of Middle East & Africa 116

10 Competitive Landscape

10.1 Introduction 119

11 Company Profile

11.1 Abbott 120

11.1.1 Company Overview 120

11.1.2 Financial Overview 120

11.1.3 Products/Services Offered 121

11.1.4 Key Developments 121

11.1.5 SWOT Analysis 121

11.1.6 Key Strategies 121

11.2 Analytik Jena AG 122

11.2.1 Financial Overview 122

11.2.2 Products/Services Offered 123

11.2.3 Key Developments 123

11.2.4 SWOT Analysis 123

11.2.5 Key Strategies 123

11.3 Becton, Dickinson And Company 124

11.3.1 Company Overview 124

11.3.2 Financial Overview 124

11.3.3 Products/Services Offered 125

11.3.4 Key Developments 125

11.3.5 SWOT Analysis 125

11.3.6 Key Strategies 126

11.4 Biocartis 127

11.4.1 Company Overview 127

11.4.2 Financial Overview 127

11.4.3 Products/Services Offered 128

11.4.4 Key Developments 128

11.4.5 SWOT Analysis 128

11.4.6 Key Strategies 128

11.5 BioMérieux Inc. 129

11.5.1 Company Overview 129

11.5.2 Financial Overview 129

11.5.3 Products/Services Offered 130

11.5.4 Key Developments 130

11.5.5 SWOT Analysis 130

11.5.6 Key Strategies 130

11.6 Cepheid 131

11.6.1 Company Overview 131

11.6.2 Financial Overview 131

11.6.3 Products/Services Offered 132

11.6.4 Key Developments 132

11.6.5 SWOT Analysis 133

11.6.6 Key Strategies 133

11.7 DiaSorin S.P.A. 134

11.7.1 Company Overview 134

11.7.2 Financial Overview 134

11.7.3 Products/Services Offered 135

11.7.4 Key Developments 135

11.7.5 SWOT Analysis 135

11.7.6 Key Strategies 135

11.8 F. Hoffmann-La Roche Ltd 136

11.8.1 Company Overview 136

11.8.2 Financial Overview 136

11.8.3 Products/Services Offered 137

11.8.4 Key Developments 137

11.8.5 SWOT Analysis 137

11.8.6 Key Strategies 137

11.9 GenMark Diagnostics, Inc. 138

11.9.1 Company Overview 138

11.9.2 Financial Overview 138

11.9.3 Products/Services Offered 138

11.9.4 Key Developments 138

11.9.5 SWOT Analysis 139

11.9.6 Key Strategies 139

11.10 Luminex Corporation 140

11.10.1 Company Overview 140

11.10.2 Financial Overview 140

11.10.3 Products/Services Offered 141

11.10.4 Key Developments 141

11.10.5 SWOT Analysis 141

11.10.6 Key Strategies 141

11.11 Meridian Bioscience, Inc. 142

11.11.1 Company Overview 142

11.11.2 Financial Overview 142

11.11.3 Products/Services Offered 143

11.11.4 Key Developments 143

11.11.5 SWOT Analysis 143

11.11.6 Key Strategies 143

11.12 Quidel Corporation 144

11.12.1 Company Overview 144

11.12.2 Financial Overview 144

11.12.3 Products/Services Offered 145

11.12.4 Key Developments 145

11.12.5 SWOT Analysis 145

11.12.6 Key Strategies 145

11.13 SA Scientific 146

11.13.1 Company Overview 146

11.13.2 Financial Overview 146

11.13.3 Products/Services Offered 146

11.13.4 Key Developments 146

11.13.5 SWOT Analysis 147

11.13.6 Key Strategies 147

11.14 Thermo Fisher Scientific Inc. 148

11.14.1 Company Overview 148

11.14.2 Financial Overview 148

11.14.3 Products/Services Offered 149

11.14.4 Key Developments 149

11.14.5 SWOT Analysis 149

11.14.6 Key Strategies 149

12 Appendix

12.1 Discussion Blue Print 150

13 List Of Tables

TABLE 1 MARKET SYNOPSIS 17

TABLE 2 PRIMARY INTERVIEWS 21

TABLE 3 PRICING RANGE OF INFLUENZA DIAGNOSTICS 31

TABLE 4 PRICING RANGE OF TEST TYPE 31

TABLE 5 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 33

TABLE 6 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR TYPE A FLU, BY REGION, 2020–2027 (USD MILLION) 34

TABLE 7 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR TYPE B FLU, BY REGION, 2020–2027 (USD MILLION) 35

TABLE 8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR TYPE C FLU, BY REGION, 2020–2027 (USD MILLION) 36

TABLE 9 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 37

TABLE 10 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY REGION, 2020–2027 (USD MILLION) 39

TABLE 11 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY REGION, 2020–2027 (USD MILLION) 40

TABLE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 41

TABLE 13 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR HOSPITALS & CLINICAL LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 14 GLOBAL INFLUENZA DIAGNOSTICS MARKET, FOR POINT-OF-CARE TESTING, BY REGION, 2020–2027 (USD MILLION) 43

TABLE 15 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 44

TABLE 16 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 46

TABLE 17 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 47

TABLE 18 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 47

TABLE 19 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 20 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 48

TABLE 21 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 49

TABLE 22 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 49

TABLE 23 AMERICAS: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 49

TABLE 24 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 50

TABLE 25 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 50

TABLE 26 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 50

TABLE 27 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 28 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 51

TABLE 29 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 30 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 52

TABLE 31 NORTH AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 52

TABLE 32 US: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 53

TABLE 33 US: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 53

TABLE 34 US: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 53

TABLE 35 US: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 36 US: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 37 US: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 54

TABLE 38 US: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 55

TABLE 39 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 55

TABLE 40 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 55

TABLE 41 CANADA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 42 CANADA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 56

TABLE 43 CANADA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 44 CANADA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 57

TABLE 45 CANADA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 57

TABLE 46 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 58

TABLE 47 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 58

TABLE 48 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 58

TABLE 49 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 50 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 59

TABLE 51 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 60

TABLE 52 LATIN AMERICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 60

TABLE 53 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2020–2027 (USD MILLION) 61

TABLE 54 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 62

TABLE 55 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 62

TABLE 56 EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 62

TABLE 57 EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 58 EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 63

TABLE 59 EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 64

TABLE 60 EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 64

TABLE 61 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 64

TABLE 62 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 65

TABLE 63 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 65

TABLE 64 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 65 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 66

TABLE 66 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 67 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 67

TABLE 68 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 67

TABLE 69 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 68

TABLE 70 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 68

TABLE 71 GERMANY: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 68

TABLE 72 GERMANY: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 73 GERMANY: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 69

TABLE 74 GERMANY: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 70

TABLE 75 GERMANY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 70

TABLE 76 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 70

TABLE 77 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 71

TABLE 78 FRANCE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 79 FRANCE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 71

TABLE 80 FRANCE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 81 FRANCE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 72

TABLE 82 FRANCE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 72

TABLE 83 UK: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 73

TABLE 84 UK: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 73

TABLE 85 UK: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 73

TABLE 86 UK: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 87 UK: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 88 UK: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 74

TABLE 89 UK: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 75

TABLE 90 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 75

TABLE 91 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 75

TABLE 92 ITALY: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 93 ITALY: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 76

TABLE 94 ITALY: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 95 ITALY: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 77

TABLE 96 ITALY: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 77

TABLE 97 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 78

TABLE 98 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 78

TABLE 99 SPAIN: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 78

TABLE 100 SPAIN: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 101 SPAIN: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 102 SPAIN: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 79

TABLE 103 SPAIN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 80

TABLE 104 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 80

TABLE 105 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 80

TABLE 106 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 107 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 81

TABLE 108 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 109 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 82

TABLE 110 REST OF WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 82

TABLE 111 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 83

TABLE 112 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 83

TABLE 113 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 83

TABLE 114 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 115 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 84

TABLE 116 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 85

TABLE 117 EASTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 85

TABLE 118 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 86

TABLE 119 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 87

TABLE 120 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 87

TABLE 121 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 122 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 88

TABLE 123 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 124 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 89

TABLE 125 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 89

TABLE 126 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 90

TABLE 127 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 90

TABLE 128 CHINA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 90

TABLE 129 CHINA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 130 CHINA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 131 CHINA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 91

TABLE 132 CHINA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 92

TABLE 133 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 92

TABLE 134 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 92

TABLE 135 JAPAN: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 136 JAPAN: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 93

TABLE 137 JAPAN: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 138 JAPAN: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 94

TABLE 139 JAPAN: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 94

TABLE 140 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 95

TABLE 141 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 95

TABLE 142 INDIA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 95

TABLE 143 INDIA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 144 INDIA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 145 INDIA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 96

TABLE 146 INDIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 97

TABLE 147 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 97

TABLE 148 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 97

TABLE 149 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 150 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 98

TABLE 151 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 152 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 99

TABLE 153 AUSTRALIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 99

TABLE 154 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 100

TABLE 155 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 100

TABLE 156 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 100

TABLE 157 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 158 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 101

TABLE 159 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 102

TABLE 160 SOUTH KOREA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 102

TABLE 161 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 102

TABLE 162 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 103

TABLE 163 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 164 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 103

TABLE 165 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 166 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 104

TABLE 167 REST OF ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 104

TABLE 168 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 105

TABLE 169 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 106

TABLE 170 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 106

TABLE 171 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 172 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 107

TABLE 173 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 174 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 108

TABLE 175 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 108

TABLE 176 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 109

TABLE 177 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 109

TABLE 178 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 109

TABLE 179 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 180 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 181 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 110

TABLE 182 SAUDI ARABIA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 111

TABLE 183 EGYPT: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 111

TABLE 184 EGYPT: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 111

TABLE 185 EGYPT: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 186 EGYPT: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 112

TABLE 187 EGYPT: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 188 EGYPT: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 113

TABLE 189 EGYPT: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 113

TABLE 190 UAE: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 114

TABLE 191 UAE: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 114

TABLE 192 UAE: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 114

TABLE 193 UAE: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 194 UAE: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 195 UAE: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 115

TABLE 196 UAE: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 116

TABLE 197 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020–2027 (USD MILLION) 116

TABLE 198 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020–2027 (USD MILLION) 116

TABLE 199 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR TRADITIONAL DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 200 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR SEROLOGICAL ASSAYS, BY TYPE, 2020–2027 (USD MILLION) 117

TABLE 201 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR MOLECULAR DIAGNOSTIC TESTS, BY TYPE, 2020–2027 (USD MILLION) 118

TABLE 202 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, FOR RT-PCR, BY TYPE, 2020–2027 (USD MILLION) 118

TABLE 203 REST OF MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 118

TABLE 204 TOP MANUFACTURERS IN THE GLOBAL INFLUENZA DIAGNOSTICS MARKET 119

14 List Of Figures

FIGURE 1 GLOBAL INFLUENZA DIAGNOSTICS MARKET: MARKET STRUCTURE 19

FIGURE 2 RESEARCH PROCESS 20

FIGURE 3 TOP-DOWN & BOTTOM-UP APPROACH 23

FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL INFLUENZA DIAGNOSTICS MARKET 24

FIGURE 5 PORTER’S FIVE FORCES ANALYSIS: GLOBAL INFLUENZA DIAGNOSTICS MARKET 28

FIGURE 6 VALUE CHAIN: GLOBAL INFLUENZA DIAGNOSTICS MARKET 30

FIGURE 7 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY TYPE OF FLU, 2020 (%) 33

FIGURE 8 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TYPE OF FLU, 2020 & 2027 (USD MILLION) 34

FIGURE 9 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY TEST TYPE, 2020 (%) 37

FIGURE 10 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY TEST TYPE, 2020 & 2027 (USD MILLION) 38

FIGURE 11 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY END USER, 2020 (%) 41

FIGURE 12 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY END USER, 2020 & 2027 (USD MILLION) 42

FIGURE 13 GLOBAL INFLUENZA DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 45

FIGURE 14 GLOBAL INFLUENZA DIAGNOSTICS MARKET, BY REGION, 2020 & 2027 (USD MILLION) 45

FIGURE 15 AMERICAS: INFLUENZA DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 47

FIGURE 16 EUROPE: INFLUENZA DIAGNOSTICS MARKET SHARE, BY REGION, 2020 (%) 61

FIGURE 17 WESTERN EUROPE: INFLUENZA DIAGNOSTICS MARKET SHARE, BY COUNTRY, 2020 (%) 65

FIGURE 18 ASIA-PACIFIC: INFLUENZA DIAGNOSTICS MARKET SHARE, BY COUNTRY, 2020 (%) 87

FIGURE 19 MIDDLE EAST & AFRICA: INFLUENZA DIAGNOSTICS MARKET SHARE, BY COUNTRY, 2020 (%) 106